As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
To read the full story
Related Article
- Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
- Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
February 3, 2023
- Takeda’s H1 Sales Up 10% Backed by Robust Mainstays, Hefty FX Gains
October 28, 2022
- Takeda’s Q1 Sales Up 2.4% Despite Diabetes Divesture Last Year, Gets Hefty FX Gains
July 29, 2022
- Takeda’s FY2021 Sales Up 11.6%; Weak Yen Tailwind for Revenue, but Drags Profits
May 12, 2022
- Takeda Delivers Growth in All Focus Therapeutic Areas in April-December
February 4, 2022
- Takeda’s H1 Sales Log Two-Digit Growth Driven by Global Brands, FDA Wraps Up Plant Re-Inspection
October 29, 2021
- Takeda to Challenge Irish Authorities’ Break Fee Tax Assessment
August 3, 2021
- Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
May 12, 2021
- Takeda’s 9-Month Sales Skid 3.6% on Dips in Rare Diseases, Neuroscience
February 5, 2021
- Takeda Done with Majority of Non-Core Asset Divestitures with US$10 Billion Target Achieved: CEO
October 30, 2020
- Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies
October 30, 2020
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
BUSINESS
- Women Exec Ratio 14.7% among TSE Prime Drug Makers, Wholesalers; Astellas Leads the Way at 30%
June 2, 2023
- CSL Behring Launches App to Manage HAE Records
June 2, 2023
- Japan Pharma Market Grows for 2 Years Running with 2.6% Rise in FY2022: IQVIA
June 2, 2023
- Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
- Ferring Japan Recalling Fertility Drug Lutinus after Bacteria Detection
June 2, 2023
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…